S'abonner

Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004–18 - 25/11/21

Doi : 10.1016/S1473-3099(21)00071-2 
Eric P F Chow, PhD a, b, c, , , Allison Carter, PhD d, f, , , Tobias Vickers, MBBS d, Christopher K Fairley, ProfPhD a, b, Anna McNulty, MMed e, g, Rebecca J Guy, ProfPhD d, David G Regan, PhD d, Andrew E Grulich, ProfPhD d, Denton Callander, PhD d, h, Laila Khawar, MPH d, Dorothy A Machalek, PhD c, d, i, Basil Donovan, ProfMD d, g
a Melbourne Sexual Health Centre, Alfred Health, Melbourne, VIC, Australia 
b Central Clinical School, Monash University, Melbourne, VIC, Australia 
c Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia 
d The Kirby Institute, University of New South Wales Sydney, Sydney, NSW, Australia 
e School of Public Health and Community Medicine, University of New South Wales Sydney, Sydney, NSW, Australia 
f Simon Fraser University, Burnaby, BC, Canada 
g Sydney Sexual Health Centre, Sydney Hospital, Sydney, NSW, Australia 
h Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA 
i Centre for Women’s Infectious Diseases, The Royal Women’s Hospital, Parkville, VIC, Australia 

* Correspondence to: Dr Eric Chow, Melbourne Sexual Health Centre, Alfred Health, Melbourne, VIC 3053, Australia Melbourne Sexual Health Centre Alfred Health Melbourne VIC 3053 Australia ** Dr Allison Carter, The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia The Kirby Institute University of New South Wales Sydney NSW 2052 Australia

Summary

Background

In Australia, the government-funded human papillomavirus (HPV) vaccination programme was introduced in April, 2007, for girls and young women, and in February, 2013, for boys. As of Dec 31, 2018, all Australian-born female individuals younger than 38 years and male individuals younger than 21 years have been eligible for the free quadrivalent or nonavalent HPV vaccine. We aimed to examine the trends in genital wart diagnoses among Australian-born female and heterosexual male individuals who attended sexual health clinics throughout Australia before and after the introduction of the gender-neutral HPV vaccination programme in February, 2013.

Methods

We did a serial cross-sectional analysis of genital wart diagnoses among Australian-born female and heterosexual male individuals attending a national surveillance network of 35 clinics between Jan 1, 2004, and Dec 31, 2018. We calculated prevalence ratios of genital warts, using log-binomial regression models, for the female-only vaccination period (July 1, 2007, to Feb 28, 2013), gender-neutral vaccination period (March 1, 2013, to Dec 31, 2018), and the whole vaccination period (July 1, 2007, to Dec 31, 2018) compared with the pre-vaccination period (Jan 1, 2004, to June 30, 2007).

Findings

We included 121 038 men and 116 341 women in the analysis. Overall, we observed a 58% reduction (prevalence ratio 0·42, 95% CI 0·40–0·44) in genital wart diagnoses in female individuals and a 45% reduction (0·55, 0·53–0·57) in genital wart diagnoses in heterosexual male individuals after the introduction of the vaccination programme in 2007. The largest reduction in genital warts was observed in younger individuals, and there was a decreasing magnitude of reduction with increasing age (80%, 72%, 61%, 41%, and 16% reductions in female individuals aged 15–20 years, 21–25 years, 26–30 years, 31–35 years, and ≥36 years, respectively; 70%, 61%, 49%, 37%, and 29% reductions in male individuals aged 15–20 years, 21–25 years, 26–30 years, 31–35 years, and ≥36 years, respectively). Significant reductions observed in female individuals (0·32, 0·28–0·36) and male individuals (0·51, 0·43–0·61) aged 15–20 years in the female-only vaccination period were followed by a more substantial reduction in female individuals (0·07, 0·06–0·09) and male individuals (0·11, 0·08–0·15) aged 15–20 years in the gender-neutral vaccination period.

Interpretation

The national gender-neutral HPV vaccination programme has led to substantial and ongoing reduction in genital warts among Australian female and heterosexual male individuals, with a marked reduction in young individuals who received the vaccine at school.

Funding

Seqirus Australia and the Australian Government Department of Health.

Le texte complet de cet article est disponible en PDF.

Plan


© 2021  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 21 - N° 12

P. 1747-1756 - décembre 2021 Retour au numéro
Article précédent Article précédent
  • The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation
  • Bart J Currie, Mark Mayo, Linda M Ward, Mirjam Kaestli, Ella M Meumann, Jessica R Webb, Celeste Woerle, Robert W Baird, Ric N Price, Catherine S Marshall, Anna P Ralph, Emma Spencer, Jane Davies, Sarah E Huffam, Sonja Janson, Sarah Lynar, Peter Markey, Vicki L Krause, Nicholas M Anstey
| Article suivant Article suivant
  • Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology
  • George R Thompson, Thuy Le, Ariya Chindamporn, Carol A Kauffman, Ana Alastruey-Izquierdo, Neil M Ampel, David R Andes, Darius Armstrong-James, Olusola Ayanlowo, John W Baddley, Bridget M Barker, Leila Lopes Bezerra, Maria J Buitrago, Leili Chamani-Tabriz, Jasper F W Chan, Methee Chayakulkeeree, Oliver A Cornely, Cao Cunwei, Jean-Pierre Gangneux, Nelesh P Govender, Ferry Hagen, Mohammad T Hedayati, Tobias M Hohl, Grégory Jouvion, Chris Kenyon, Christopher C Kibbler, Nikolai Klimko, David C M Kong, Robert Krause, Low Lee Lee, Graeme Meintjes, Marisa H Miceli, Peter-Michael Rath, Andrej Spec, Flavio Queiroz-Telles, Ebrahim Variava, Paul E Verweij, Ilan S Schwartz, Alessandro C Pasqualotto

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.